ClinicalTrials.gg
RecruitingNCT06626269HORIZONUpdated Nov 12, 2026

Identification of Innovative Biomarkers Related to the Immune System or Tumor Microenvironment to Promote the Efficacy of Immunotherapies

An interventional study of Blood sample and Tumor tissue in Advanced Digestive Cancer and Advanced Gynecologic Cancer, sponsored by Centre Hospitalier Universitaire de Besancon. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Centre Hospitalier Universitaire de Besancon · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.
Updated Nov 12, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
700
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 63 studies in Gastrointestinal Neoplasms with a site in France — 27 open to participants now, 32 under way, 3 of them phase 3. Gastrointestinal Neoplasms · France.

Planned enrollment
7th of 51
700 · median 200
Started
2025
with 9 others
No phase
23 of 63
13 open now
Primary completion
2030-02
later than 26 of 31 live
Registered
47th of 63
by date

Among the 63 studies in Gastrointestinal Neoplasms with a site in France, this one is the 7th largest by planned enrollment of the 51 interventional ones that give a count, is one of 10 that started in 2025, is one of 23 with no phase, reaches primary completion later than 26 of the 31 other live ones, and was the 47th registered.

Gastrointestinal Neoplasms

698 studies on the registry are indexed under Gastrointestinal Neoplasms; 211 are open to participants now.

Browse Gastrointestinal Neoplasms studies →

Open to participants now

27 of the 63 studies in Gastrointestinal Neoplasms with a site in France are open now. Recruiting first, the newest first:

21 more — sign in →

All 27 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 160 Gastrointestinal Neoplasms studies recruiting now, 121 (76%) set no upper age limit and 19 (12%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies in Gastrointestinal Neoplasms with a site in France, or all of them as a file.
02

Study summary

The immune system may be involved in the recognition and destruction of tumor cells or cells undergoing transformation. It is also currently accepted that the quality of immune responses can influence the evolution of cancers after chemotherapy.

In this context, it is possible to assess the presence of specific T cells in patients\' blood and to correlate the presence of specific memory lymphocytes with the quality of long-term clinical protection.

The analysis of immune responses can also be based on i) analysis of the tumor microenvironment (analysis of surgical samples or biopsies) or ii) analysis of molecules secreted in plasma.

Today, the immunotherapies can generate clinical responses in several cancers (for 15 to 25% of patients with melanomas, bladder, lung, kidney or gastric cancers). But the development of these drugs raises two unresolved questions: i) what immunological parameters predict the efficacy of these treatments? ii) why do some cancers remain refractory to the efficacy of these immunomodulatory drugs? It is therefore necessary to identify biomarkers for prognostic stratification and monitoring of patients treated by immunotherapy.

The primary objective of our research team is to identify biomarkers related to the immune system or tumor microenvironment in order to better define patient eligibility criteria for immunotherapy strategies.

03

Conditions studied

  • Advanced Digestive Cancer
  • Advanced Gynecologic Cancer

Keywords

  • biomarker
  • immunology
  • gynecologic cancer
  • digestive cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

General inclusion criteria:

  • Patients ≥ 18 years old
  • more than 6 months of as assessed by the investigator
  • Performance status 0 ; 1 or 2
  • Patient affiliated to or beneficiary of French social security system
  • of the subject to participate in the study

Specific eligibility criteria:

- Cohort A [Patients with advanced digestive or gynecological cancers eligible to immunotherapies]: Patients with locally advanced or digestive or gynecological cancers A1: hepatocellular carcinoma eligible to immunotherapy ± antiangiogenic A2: biliary tract carcinoma eligible to chemo-immunotherapy A3: oesogastric carcinoma eligible to chemo-immunotherapy A4: other digestive localizations eligible to immunotherapy (anti-PD1/PDL1 ± anti-CTLA4) ± chemotherapy A5: gynecological cancers eligible to chemo-immunotherapy

- Cohort B [Patients with advanced digestive or gynecological cancers eligible to chemotherapy or targeted therapy without immunotherapy]: Patients with locally advanced or metastatic digestive or gynecological cancers B1: hepatocellular carcinoma eligible to antiangiogenic or chemotherapy B2: biliary tract carcinoma eligible to chemotherapy B3: oesogastric carcinoma eligible to chemotherapy B4: other digestive localizations eligible to chemotherapy and/or targeted therapy B5: gynecological cancers eligible to chemotherapy and/or targeted therapy

- Cohort C [Patients with advanced digestive or gynecological cancers eligible to surgery of metastasis after chemotherapy]: Patients with liver metastasis of colorectal cancer or peritoneal metastasis of ovarian cancer eligible to surgical resection

Exclusion criteria

EXCLUSION CRITERIA :

General exclusion criteria:

  • Patient under guardianship, curatorship or under the protection of justice
  • Patient with any medical or psychiatric condition or disease, which would make the patient inappropriate for entry into this study
  • Patient unlikely to cooperate with the study and/or poor cooperation anticipated by the investigator
  • Patient without health insurance
  • Pregnant women
  • Subject within the exclusion period of another study or planned by the national volunteer file
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
700 participants (estimated)

Study arms

  • Experimental
    blood test

    In cohort A: patients with advanced digestive or gynecological cancers eligible to immunotherapies. In cohort B: patients with advanced digestive or gynecological cancers eligible to treatment without immunotherapy. In cohort C: patients with advanced digestive or gynecological cancers eligible to surgery of metastasis after chemotherapy.

    Diagnostic Test: Blood sample · Other: Tumor tissue

Interventions

  • Diagnostic testBlood sample

    In cohort A: 3 or 4 blood samples (for plasma and PBMC collection) : at baseline (before immunotherapy initiation); at 3 months ; at 12 months; on case of severe or unexpected toxicity. In cohort B: 3 blood sampes (for plasma and PBMC collection): at baseline (before treatment initiation); at 3 months ; at 12 months In cohort C: 2 blood samples (for plasma and PBMC collection) : at baseline (at the time of surgery); at 3 months (after surgery)

  • OtherTumor tissue

    Cohort A and B: 1 tumor block in paraffin at diagnosis + 1 tumor block in paraffin at progression (optional) Cohort C: Fresh tumoral tissue fragments for TIL and CAF + 1 tumor block in paraffin at time of surgery.

06

What researchers measure

Primary outcomes

  1. for cohorts A and B: Progression free survival (PFS) at 6 months post treatment initiation

    Progression free survival (PFS) at 6 months post treatment initiation, defined as: * non progressive alive patients: if patients are alive without progression in the 6 months from the date of treatment initiation * or progressive or death patients: if patients are identified with a progression or a death in the 6 months from the date of treatment initiation * patients without progression or death and with follow up bellow than 6 months are not assessable for PFS status at 6 months Progression-free survival (PFS): defined as the delay from the date of treatment initiation to the disease progression or death from any cause whichever occurs first. Alive patient without progression will be censored at last radiological evaluation available showing no progression.

    Time frame: 6 months post treatment initiation

  2. For cohort C: Relapse free survival (RFS) at 6 months after surgery of metastases

    RFS: defined as the delay from the date of surgery of metastases to the disease relapse or death from any cause whichever occurs first. Alive patient without relapse will be censored at last radiological evaluation available showing no relapse.

    Time frame: 6 months after surgery of metastases

07

Study locations

1 of 2 sites recruiting
  • University Hospital of Besançon
    Besançon, 25000, France
    Recruiting
    • Christophe BORG, Pr · Principal investigator
  • Georges François Leclerc center
    Dijon, 21000, France
    Not yet recruiting
    • François GHIRINGHELLI, Pr · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Feb 2030, 60 months after the start.

Of 154 non-industry interventional studies with no phase under Gastrointestinal Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 71. This study's planned 60 months is above that.

Counting every sponsor, half of 164 studies reached it within 36 months; a quarter within 17 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2024
First posted
Oct 3, 2024
StartActual
Feb 10, 2025
Primary completionEst.
Feb 2030
CompletionEst.
Feb 2032
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • University Hospital of Besançon · Besançon, France
Show 1 removed
  • University Hospital of Besançon · Besancon, France
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    1 site added, 1 site removed
    Show site
    • University Hospital of Besançon · Besançon, France
    Show 1 removed
    • University Hospital of Besançon · Besancon, France
    + 3 other changes: verification date, oversight details and criteria formatting

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06626269
Responsible party
Sponsor
First posted
Oct 3, 2024
Start date
Feb 10, 2025
Primary completion
Feb 2030 (estimated)
Completion
Feb 2032 (estimated)
Last update
Nov 12, 2026

Study contacts

Christophe BORG, PU-PH
Contact
xtoph.borg@gmail.com
+33(0)381668166

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion